Literature DB >> 16331794

Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7.

Peter A Merkel1, Philip Seo, Peter Aries, Tuhina Neogi, Alexandra Villa-Forte, Maarten Boers, David Cuthbertson, David T Felson, Bernhard Hellmich, Gary S Hoffman, David R Jayne, Cees G M Kallenberg, Jeffrey Krischer, Alfred Mahr, Eric L Matteson, Ulrich Specks, Raashid Luqmani, John Stone.   

Abstract

The complexity of assessing disease activity, disease status, and damage in the vasculitides reflects the multisystemic pathologic manifestations of these often chronic illnesses. Major progress has been made in the past decade in the development of validated and widely accepted outcome measures for use in clinical trials. Over time, these tools have been regularly revised, expanded, and supplemented with new measures of disease prognosis and damage. As a result clinical research in this area has become increasingly complex. This article critically reviews the current status of tools for assessing disease activity and damage in "ANCA-associated" vasculitides (Wegener's granulomatosis and microscopic polyangiitis), summarizes the current level of validation of each measure, addresses central problems and controversies to be considered during development of new vasculitis assessment tools, and proposes a series of research agendas for consideration by the vasculitis research community.

Entities:  

Mesh:

Year:  2005        PMID: 16331794

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  12 in total

1.  Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index.

Authors:  Ravi Suppiah; Oliver Flossman; Chetan Mukhtyar; Federico Alberici; Bo Baslund; Denise Brown; Nadeem Hasan; Julia Holle; Zdenka Hruskova; David Jayne; Andrew Judge; Mark A Little; Peter A Merkel; Alessandra Palmisano; Philip Seo; Coen Stegeman; Vladimir Tesar; Augusto Vaglio; Kerstin Westman; Raashid Luqmani
Journal:  Ann Rheum Dis       Date:  2010-08-24       Impact factor: 19.103

Review 2.  EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.

Authors:  Bernhard Hellmich; Oliver Flossmann; Wolfgang L Gross; Paul Bacon; Jan Willem Cohen-Tervaert; Loic Guillevin; David Jayne; Alfred Mahr; Peter A Merkel; Heiner Raspe; David G I Scott; James Witter; Hasan Yazici; Raashid A Luqmani
Journal:  Ann Rheum Dis       Date:  2006-12-14       Impact factor: 19.103

Review 3.  Development of comprehensive disease assessment in systemic vasculitis.

Authors:  Oliver Flossmann; Paul Bacon; Kirsten de Groot; David Jayne; Niels Rasmussen; Philip Seo; Kerstin Westman; Raashid Luqmani
Journal:  Ann Rheum Dis       Date:  2006-05-25       Impact factor: 19.103

4.  The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis.

Authors:  Peter A Merkel; Sibel Z Aydin; Maarten Boers; Haner Direskeneli; Karen Herlyn; Philip Seo; Ravi Suppiah; Gunnar Tomasson; Raashid A Luqmani
Journal:  J Rheumatol       Date:  2011-07       Impact factor: 4.666

5.  Transcription of proteinase 3 and related myelopoiesis genes in peripheral blood mononuclear cells of patients with active Wegener's granulomatosis.

Authors:  Chris Cheadle; Alan E Berger; Felipe Andrade; Regina James; Kristen Johnson; Tonya Watkins; Jin Kyun Park; Yu-Chi Chen; Eva Ehrlich; Marissa Mullins; Francis Chrest; Kathleen C Barnes; Stuart M Levine
Journal:  Arthritis Rheum       Date:  2010-06

6.  Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.

Authors:  P A Merkel; D D Cuthbertson; B Hellmich; G S Hoffman; D R W Jayne; C G M Kallenberg; J P Krischer; R Luqmani; A D Mahr; E L Matteson; U Specks; J H Stone
Journal:  Ann Rheum Dis       Date:  2008-07-29       Impact factor: 19.103

7.  Current status of outcome measure development in vasculitis.

Authors:  Peter A Merkel; Sibel Z Aydin; Maarten Boers; Christina Cornell; Haner Direskeneli; Don Gebhart; Gulen Hatemi; Raashid Luqmani; Eric L Matteson; Nataliya Milman; Joanna Robson; Philip Seo; Gunnar Tomasson
Journal:  J Rheumatol       Date:  2014-01-15       Impact factor: 4.666

8.  Assessment of damage in vasculitis: expert ratings of damage.

Authors:  Philip Seo; David Jayne; Raashid Luqmani; Peter A Merkel
Journal:  Rheumatology (Oxford)       Date:  2009-05-19       Impact factor: 7.580

9.  Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9.

Authors:  Peter A Merkel; Karen Herlyn; Alfred D Mahr; Tuhina Neogi; Philip Seo; Michael Walsh; Maarten Boers; Raashid Luqmani
Journal:  J Rheumatol       Date:  2009-10       Impact factor: 4.666

10.  Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener's granulomatosis.

Authors:  Alfred D Mahr; Tuhina Neogi; Michael P Lavalley; John C Davis; Gary S Hoffman; W Joseph McCune; Ulrich Specks; Robert F Spiera; E William St Clair; John H Stone; Peter A Merkel
Journal:  Arthritis Rheum       Date:  2008-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.